Compare RNGR & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNGR | BCYC |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United Kingdom |
| Employees | 2300 | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.6M | 310.7M |
| IPO Year | 2017 | 2019 |
| Metric | RNGR | BCYC |
|---|---|---|
| Price | $15.92 | $4.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $20.00 | $13.90 |
| AVG Volume (30 Days) | 173.9K | ★ 313.1K |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 6.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.86 | N/A |
| Revenue Next Year | $4.37 | N/A |
| P/E Ratio | $132.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.14 | $3.97 |
| 52 Week High | $18.82 | $9.18 |
| Indicator | RNGR | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 47.94 | 34.12 |
| Support Level | $14.99 | N/A |
| Resistance Level | $16.89 | $4.75 |
| Average True Range (ATR) | 0.59 | 0.18 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 54.55 | 9.68 |
Ranger Energy Services Inc offers high specification mobile rig well services, cased hole wireline services, and ancillary services in the U.S. oil and gas industry. Its services facilitate operations throughout the lifecycle of a well, including the completion, production, maintenance, intervention, workover, and abandonment phases. The company's reportable segments are: High Specification Rigs, Wireline Services, Processing Solutions and Ancillary Services. Maximum revenue is generated from the High Specification Rigs segment, which offers high specification well service rigs and complementary equipment and services to facilitate operations throughout the lifecycle of a well. The high specification rig services consist of well completion support, workovers, and well maintenance services.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.